Edition:
United States

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

6.10USD
22 May 2018
Change (% chg)

$0.05 (+0.83%)
Prev Close
$6.05
Open
$6.08
Day's High
$6.10
Day's Low
$6.06
Volume
711
Avg. Vol
80,624
52-wk High
$25.22
52-wk Low
$4.93

Select another date:

Wed, May 9 2018

BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock

* RA PHARMA - ENTERED SALES AGREEMENT WITH STIFEL PURSUANT TO WHICH CO MAY SELL, UP TO $50 MILLION OF SHARES OF COMMON STOCK, THROUGH STIFEL AS SALES AGENT Source text: (https://bit.ly/2G0vejI) Further company coverage:

BRIEF-Ra Pharmaceuticals Q1 Loss Per Share $0.61

* RA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ra Pharmaceuticals Announces Presentation Of RA101495 SC Phase 2 gMG Clinical Trial Design At 70Th Annual AAN Meeting

* RA PHARMACEUTICALS ANNOUNCES PRESENTATION OF RA101495 SC PHASE 2 GMG CLINICAL TRIAL DESIGN AT THE 70TH ANNUAL AAN MEETING

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

* RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share

* RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 1B Pharmacokinetic Study Evaluating Ra101495 Sc In Patients With Renal Impairment

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Select another date: